Literature DB >> 7509719

Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer.

S Arao1, H Suwa, M Mandai, H Tashiro, K Miyazaki, H Okamura, H Nomura, H Hiai, M Fukumoto.   

Abstract

Resistance to chemotherapy is the major obstacle to controlling malignant tumors. To characterize multidrug resistance phenotype in human primary ovarian cancer without chemotherapy, expressions of the mdr1 gene in 52 cases of ovarian cancer (44 common epithelial, 5 nonepithelial, and 3 metastatic cancers) were analyzed by polymerase chain reaction of RNA after reverse transcription. Furthermore, localization of P-glycoprotein, which is encoded by the mdr1 gene, was studied immunohistochemically. Although overall expression of the mdr1 gene was relatively low, its expression level was the highest in well-differentiated cancer tissues. Serous and mucinous adenocarcinomas showed higher levels of expression compared with clear cell and endometrioid carcinomas. P-glycoprotein was positive on luminal surfaces of lining cells of ovarian cancer and on those of inclusion cysts from which epithelial ovarian cancer is considered to develop. Thus, some ovarian cancer cases before chemotherapy are intrinsically multidrug resistant, which can be determined by mdr1 gene expression, and this phenotype should be taken into account for effective chemotherapy of ovarian epithelial carcinomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509719

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Overcoming drug resistance in ovarian carcinoma.

Authors:  P M Fracasso
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

Review 2.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

3.  A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.

Authors:  E Moran; A Larkin; G Doherty; P Kelehan; S Kennedy; M Clynes
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

Review 4.  Development of multidrug-resistance convertors: sense or nonsense?

Authors:  L van Zuylen; K Nooter; A Sparreboom; J Verweij
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

5.  Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.

Authors:  Ashley M Laughney; Eunha Kim; Melissa M Sprachman; Miles A Miller; Rainer H Kohler; Katy S Yang; James D Orth; Timothy J Mitchison; Ralph Weissleder
Journal:  Sci Transl Med       Date:  2014-11-05       Impact factor: 17.956

6.  Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Authors:  Donavon Hiss
Journal:  J Oncol       Date:  2012-02-06       Impact factor: 4.375

7.  Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas.

Authors:  H Suwa; G Ohshio; T Imamura; G Watanabe; S Arii; M Imamura; S Narumiya; H Hiai; M Fukumoto
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  Expression of the thymidine phosphorylase gene in epithelial ovarian cancer.

Authors:  K Hata; T Kamikawa; S Arao; H Tashiro; H Katabuchi; H Okamura; R Fujiwaki; K Miyazaki; M Fukumoto
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.

Authors:  Xiaoqian Yang; Arun K Iyer; Amit Singh; Edwin Choy; Francis J Hornicek; Mansoor M Amiji; Zhenfeng Duan
Journal:  Sci Rep       Date:  2015-02-17       Impact factor: 4.379

10.  Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tc(m)-MIBI.

Authors:  A Gruber; I Areström; D Xu; J Liliemark; S A Larsson; H Jacobsson
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.